BRPI0509976A - derivados de alfa-aminoamidas úteis no tratamento de sìndrome das pernas inquietas e distúrbios de dependência a drogas - Google Patents

derivados de alfa-aminoamidas úteis no tratamento de sìndrome das pernas inquietas e distúrbios de dependência a drogas

Info

Publication number
BRPI0509976A
BRPI0509976A BRPI0509976-5A BRPI0509976A BRPI0509976A BR PI0509976 A BRPI0509976 A BR PI0509976A BR PI0509976 A BRPI0509976 A BR PI0509976A BR PI0509976 A BRPI0509976 A BR PI0509976A
Authority
BR
Brazil
Prior art keywords
alpha
drug addiction
addiction disorders
aminoamide derivatives
derivatives useful
Prior art date
Application number
BRPI0509976-5A
Other languages
English (en)
Inventor
Claudia Besana
Elena Barbanti
Emanuela Izzo
Florian Thaler
Ruggero Fariello
Patricia Salvati
Luca Benatti
Original Assignee
Newron Pharm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Newron Pharm Spa filed Critical Newron Pharm Spa
Priority to BR122020004541-8A priority Critical patent/BR122020004541B1/pt
Publication of BRPI0509976A publication Critical patent/BRPI0509976A/pt
Publication of BRPI0509976B1 publication Critical patent/BRPI0509976B1/pt
Publication of BRPI0509976B8 publication Critical patent/BRPI0509976B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Abstract

DERIVADOS DE ALFA-AMINOAMIDAS úTEIS NO TRATAMENTO DE SìNDROME DAS PERNAS INQUIETAS E DISTúRBIOS DE DEPENDêNCIA A DROGAS. A presente invenção refere-se ao uso de certos derivados de alfa-aminoamidas no tratamento de RLS e distúrbios de dependência a drogas. Os compostos desta invenção são capazes de reduzir ou mesmo parar os sintomas de RLS e distúrbios de dependência a drogas substancialmente sem efeitos colaterais.
BRPI0509976A 2004-04-22 2005-04-19 uso de derivados de alfa-aminoamidas no tratamento de síndrome das pernas inquietas BRPI0509976B8 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122020004541-8A BR122020004541B1 (pt) 2004-04-22 2005-04-19 Uso de um derivado de alfa-aminoamida na preparação de um medicamento para tratamento de distúrbios de dependência a cocaína

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04009532A EP1588704A1 (en) 2004-04-22 2004-04-22 Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
EP04009532.5 2004-04-22
PCT/EP2005/004166 WO2005102300A1 (en) 2004-04-22 2005-04-19 α-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF RESTLESS LEGS SYNDROME AND ADDICTIVE DISORDERS

Publications (3)

Publication Number Publication Date
BRPI0509976A true BRPI0509976A (pt) 2007-10-16
BRPI0509976B1 BRPI0509976B1 (pt) 2020-10-06
BRPI0509976B8 BRPI0509976B8 (pt) 2021-05-25

Family

ID=34924693

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0509976A BRPI0509976B8 (pt) 2004-04-22 2005-04-19 uso de derivados de alfa-aminoamidas no tratamento de síndrome das pernas inquietas
BR122020004541-8A BR122020004541B1 (pt) 2004-04-22 2005-04-19 Uso de um derivado de alfa-aminoamida na preparação de um medicamento para tratamento de distúrbios de dependência a cocaína

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122020004541-8A BR122020004541B1 (pt) 2004-04-22 2005-04-19 Uso de um derivado de alfa-aminoamida na preparação de um medicamento para tratamento de distúrbios de dependência a cocaína

Country Status (25)

Country Link
US (2) US8445513B2 (pt)
EP (3) EP1588704A1 (pt)
JP (1) JP5020069B2 (pt)
KR (2) KR101195819B1 (pt)
CN (1) CN1942179B (pt)
AT (2) ATE494890T1 (pt)
AU (1) AU2005235428B2 (pt)
BR (2) BRPI0509976B8 (pt)
CA (1) CA2563674C (pt)
CY (2) CY1108494T1 (pt)
DE (2) DE602005025941D1 (pt)
DK (2) DK1900362T3 (pt)
ES (2) ES2313330T3 (pt)
HR (2) HRP20080593T3 (pt)
IL (1) IL178732A (pt)
ME (2) ME02324B (pt)
MX (1) MXPA06012163A (pt)
NO (2) NO337900B1 (pt)
NZ (1) NZ550664A (pt)
PL (2) PL1900362T3 (pt)
PT (2) PT1737438E (pt)
RS (2) RS51791B (pt)
RU (1) RU2403030C2 (pt)
SI (2) SI1900362T1 (pt)
WO (1) WO2005102300A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
CN1274306C (zh) 2001-09-03 2006-09-13 纽朗制药有限公司 包含加巴喷丁或其类似物和α－氨基酰胺的药物组合物及其止痛应用
EP1438956A1 (en) * 2003-01-16 2004-07-21 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful as antimigraine agents
US20070276046A1 (en) * 2003-08-25 2007-11-29 Patricia Salvati Alpha-Aminoamide Derivatives Useful as Anti-Inflammatory Agents
EP1588704A1 (en) 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
RS51411B (sr) * 2004-09-10 2011-02-28 Newron Pharmaceuticals S.P.A. Upotreba (r)-(halobenziloksi) benzilamino-propanamida kao selektivnih modulatora natrijumovih i/ili kalcijumovih kanala
US20060173074A1 (en) * 2004-11-10 2006-08-03 Juha Ellmen Treatment of restless legs syndrome
IN266803B (pt) 2005-12-22 2015-06-03 Newron Pharm Spa
AU2007235517B2 (en) 2006-04-03 2013-01-31 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of Restless Legs Syndrome
EP1870097A1 (en) 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
KR101491541B1 (ko) * 2006-06-19 2015-02-09 뉴론 파마슈티칼즈 에스. 피. 에이. 2-［4-(3- 및 2-플루오로벤질옥시)벤질아미노)프로판 아미드의 제조방법
GB0706630D0 (en) * 2007-04-04 2007-05-16 Glaxo Group Ltd Novel compounds
TR201802576T4 (tr) 2007-06-15 2018-03-21 Newron Pharm Spa Sübsti̇tüe edi̇lmi̇ş 2-[2-(feni̇l)eti̇lami̇no]alkanami̇t türevleri̇ ve bunlarin sodyum ve/veya kalsi̇yum kanal modülatörleri̇ olarak kullanimi
EP3257842B1 (en) * 2007-12-11 2020-11-18 Newron Pharmaceuticals S.p.A. Therapeutic use of 2-[4-(3- or 2-fluorobenzyloxy)benzylamino]propanamides with high purity degree
CN101903021B (zh) * 2007-12-19 2012-11-14 纽朗制药有限公司 用于治疗精神病的α-氨基酰胺衍生物
EP2314569A1 (en) 2009-10-22 2011-04-27 Merck Patent GmbH Novel polymorphic forms of (S)-2-[4-(3-Fluoro-benzyloxy)-benzylamino]-propionamide mesylate salt and processes of manufacturing thereof
LT2563355T (lt) 2010-04-27 2016-09-26 Newron Pharmaceuticals S.P.A. Ralfinamido metansulfonato druskų arba jų r-enentiomerų gavimo būdas
US11278651B2 (en) * 2018-10-17 2022-03-22 Gambro Lundia Ab Membrane and device for treating restless leg syndrome
CN114667963B (zh) * 2020-12-24 2024-04-26 中国科学院脑科学与智能技术卓越创新中心 一种非人灵长类动物药物成瘾性评估的装置

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1140748A (en) 1966-06-23 1969-01-22 Ici Ltd New carboxylic acid derivatives
US4049663A (en) * 1972-06-06 1977-09-20 Allen & Hanburys Limited Ethylene diamine derivatives
FR2480747A1 (fr) * 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
US4935429A (en) * 1985-10-25 1990-06-19 Dackis Charles A Method of treating psychostimulant addiction
CA1336169C (en) * 1988-03-01 1995-07-04 Walther Birkmayer Agent for treatment of parkinson's disease
IL94466A (en) * 1989-05-25 1995-01-24 Erba Carlo Spa Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
US5221536A (en) * 1990-05-07 1993-06-22 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
EP0520325A1 (de) * 1991-06-28 1992-12-30 F.Hoffmann-La Roche & Co. Aktiengesellschaft Verwendung von Monoaminoxidase-B-Hemmern zur Verhütung und Behandlung von Entzugserscheinungen nach Alkohol- und Drogenmissbrauch
GB9306886D0 (en) 1993-04-01 1993-05-26 Erba Carlo Spa Substituted (arylakoxybenzyl) aminopropanamide derivatives and process for their preparation
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
DK0828513T3 (da) * 1995-05-26 2004-04-13 Pfizer Kombinationspræparater til behandling af parkinsonisme, indeholdende selektive NMDA-antagonister
AU3155995A (en) 1995-06-17 1997-01-15 Gunter Baumann Disc-shaped member
GB9515411D0 (en) 1995-07-27 1995-09-27 Pharmacia Spa N-(4-substituted-benzyl)-2-aminolactam derivatives
GB9515412D0 (en) 1995-07-27 1995-09-27 Pharmacia Spa 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives
DE19701619B4 (de) * 1997-01-17 2007-10-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Pramipexol zur Behandlung des restless legs syndroms
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
GB9727521D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Substituted 2-benzylamino-2-phenyl-acetamide compounds
US6348074B2 (en) 1998-01-12 2002-02-19 Saga Fuel Systems, Inc. Composition as an additive to create clear stable solutions and microemulsions with a combustible liquid fuel to improve combustion
FI109453B (fi) * 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
WO2001034172A2 (en) * 1999-11-05 2001-05-17 Vela Pharmaceuticals Inc. Methods and compositions for treating reward deficiency syndrome
WO2001041763A1 (en) * 1999-12-10 2001-06-14 University Of Cincinnati Treatment of addiction disorders
US20020019421A1 (en) * 2000-07-05 2002-02-14 Roni Biberman Compositions and therapy for substance addiction
EP1406631A4 (en) * 2001-06-13 2005-03-23 Univ Michigan DOPAMIN RECEPTOR LIGANDS AND THERAPEUTIC METHODS BASED THEREFOR
EA009372B1 (ru) * 2002-05-29 2007-12-28 Ф. Хоффманн-Ля Рош Аг N-ациламинобензольные производные в качестве селективных ингибиторов моноаминооксидазы в
SI1515921T1 (sl) 2002-06-24 2006-08-31 Rockwool Int Postopek in priprava za krmiljenje proizvodnje mineralne volne z uporabo kaskadnega navijala
US6900354B2 (en) * 2002-07-15 2005-05-31 Hoffman-La Roche Inc. 3-phenyl-propionamido, 3-phenyl-acrylamido and 3-phenyl-propynamido derivatives
AR044007A1 (es) 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
JP2005060370A (ja) * 2003-07-25 2005-03-10 Kyowa Hakko Kogyo Co Ltd 医薬組成物
EP1524267A1 (en) * 2003-10-15 2005-04-20 Newron Pharmaceuticals S.p.A. Substituted benzylaminoalkylene heterocycles
EP1588704A1 (en) 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders

Also Published As

Publication number Publication date
CA2563674A1 (en) 2005-11-03
ME02324B (me) 2016-06-20
JP2007533691A (ja) 2007-11-22
CN1942179A (zh) 2007-04-04
EP1900362A2 (en) 2008-03-19
CN1942179B (zh) 2010-08-11
CA2563674C (en) 2012-12-18
JP5020069B2 (ja) 2012-09-05
HK1099216A1 (en) 2007-08-10
PT1900362E (pt) 2011-03-09
NO337900B1 (no) 2016-07-04
CY1108494T1 (el) 2014-04-09
SI1900362T1 (sl) 2011-03-31
SI1737438T1 (sl) 2008-12-31
RU2403030C2 (ru) 2010-11-10
DK1737438T3 (da) 2008-12-08
HRP20110230T1 (hr) 2011-04-30
AU2005235428B2 (en) 2010-03-18
HRP20080593T3 (en) 2008-12-31
NO20064732L (no) 2006-11-22
KR101238377B1 (ko) 2013-03-04
IL178732A0 (en) 2007-05-15
US8697738B2 (en) 2014-04-15
NO20150971L (no) 2006-11-22
US8445513B2 (en) 2013-05-21
ATE494890T1 (de) 2011-01-15
EP1737438A1 (en) 2007-01-03
RS51791B (sr) 2011-12-31
AU2005235428A1 (en) 2005-11-03
DE602005009162D1 (de) 2008-10-02
EP1900362A3 (en) 2009-04-01
DE602005025941D1 (de) 2011-02-24
PL1737438T3 (pl) 2009-01-30
BRPI0509976B8 (pt) 2021-05-25
NO338870B1 (no) 2016-10-31
WO2005102300A1 (en) 2005-11-03
ES2313330T3 (es) 2009-03-01
PT1737438E (pt) 2008-12-22
RS50667B (sr) 2010-06-30
DK1900362T3 (da) 2011-05-09
ATE405256T1 (de) 2008-09-15
EP1900362B1 (en) 2011-01-12
NZ550664A (en) 2010-08-27
CY1111656T1 (el) 2015-10-07
MXPA06012163A (es) 2007-01-17
KR101195819B1 (ko) 2012-11-05
PL1900362T3 (pl) 2011-06-30
KR20070042914A (ko) 2007-04-24
KR20120028399A (ko) 2012-03-22
IL178732A (en) 2013-01-31
ME01219B (me) 2013-06-20
RU2006137079A (ru) 2008-04-27
EP1737438B1 (en) 2008-08-20
ES2357559T3 (es) 2011-04-27
BR122020004541B1 (pt) 2021-11-09
US20130217747A1 (en) 2013-08-22
US20070203182A1 (en) 2007-08-30
BRPI0509976B1 (pt) 2020-10-06
EP1588704A1 (en) 2005-10-26

Similar Documents

Publication Publication Date Title
BRPI0509976B8 (pt) uso de derivados de alfa-aminoamidas no tratamento de síndrome das pernas inquietas
SV2008002958A (es) Uso de derivados de sulfamida heterociclo benzo-fusionado para el tratamiento del trastorno bipolar y mania referencia cruzada ref. prd2592sv
EA200701511A1 (ru) Фармацевтические композиции бендамустина, предназначенные для лиофилизации
CL2007001733A1 (es) Compuestos derivados de imidazol condensado con heterociclos nitrogenados; composicion farmaceutica; y uso para tratar o prevenir un trastorno asociado con el deterioro cognitivo, la enfermedad de alzheimer, demencia senil y demencia asociada con enfermedad de parkinson entre otras.
EA201070121A1 (ru) Лекарственная форма, содержащая слитый белок glp-1-fc
CL2007001731A1 (es) Compuestos derivados de imidazo[1,5-a]pirimidina; composicion farmaceutica; y uso para tratar o prevenir un trastorno asociado con el deterioro cognitivo, la enfermedad de alzheimer, demencia senil y demencia asociada con enfermedad de parkinson entre otras.
CL2007001732A1 (es) Compuestos derivados de imidazo[1,5-a]pirimidina; composicion farmaceutica; y uso para tratar o prevenir un trastorno asociado con el deterioro cognitivo, la enfermedad de alzheimer, demencia senil y demencia asociada con enfermedad de parkinson entre otras.
NO20074943L (no) Roflumilast for behandlingen av diabetes mellitus
MY146388A (en) Thiazole pyrazolopyrimidines as crfi receptor antagonists
NO20053509D0 (no) Anvendelse av adenosin A2a -reseptomntagonister
DE602005018763D1 (de) Dopamin-agonisten-kombinationstherapie mit sedativa zur verbesserung der schlafqualität
NO20070113L (no) Opioider for behandling av restless legs syndromet
BRPI0722054A2 (pt) Composição, kit, e métodos para diminuir um efeito colateral de tratamento com um inibidor da calcineurina, para aumentar um efeito terapêutico de um inibidor da calcineurina e para mudar a concentração de tacrolimus ou um análogo de tacrolimus em um compartimento fisiológico.
EA200701820A1 (ru) Применение диосметиновых соединений при лечении и профилактике тромботических патологий
BRPI0506970B8 (pt) derivados de alfa-aminoamida úteis no tratamento de distúrbios do trato urinário inferior
BRPI0607043A2 (pt) lacosamida para terapia de adição
MXPA05013200A (es) Derivados de estaurosporina para sindrome hipereosinofilico.
EA200700407A1 (ru) Производные хиназолина и их использования при лечении тромбоцитемии
EA200702135A1 (ru) Лечение болезни паркинсона, обструктивного синдрома апноэ во сне, слабоумия с тельцами льюи, сосудистой деменции с помощью не содержащих имидазола алкиламиновых лигандов гистаминовых н3-рецепторов
TW200716146A (en) Method for treating or preventing systemic inflammation in formula-fed infants
WO2007055804A3 (en) Methods and compositions for administration of iron for the treatment of restless leg syndrome
BRPI0606528A2 (pt) composição para uso no fabrico de medicamentos de tratamento da infertilidade masculina e uso da mesma
EA200800766A1 (ru) Ингибиторы pi3k для лечения эндометриоза
IL185807A0 (en) Use of amino-substituted benzimidazoles
MX2009005640A (es) Metodos para el tratamiento del abuso, adiccion y dependencia del alcohol.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B25G Requested change of headquarter approved

Owner name: NEWRON PHARMACEUTICALS S.P.A. (IT)

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/04/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2876 DE 18-02-2026 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.